394 related articles for article (PubMed ID: 27409709)
41. Vitamin D supplementation for sickle cell disease.
Soe HHK; Abas AB; Than NN; Ni H; Singh J; Said ARBM; Osunkwo I
Cochrane Database Syst Rev; 2020 May; 5(5):CD010858. PubMed ID: 32462740
[TBL] [Abstract][Full Text] [Related]
42. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.
Somers MJ; Paul E
J Clin Pharmacol; 2015 Apr; 55(4):368-76. PubMed ID: 25402866
[TBL] [Abstract][Full Text] [Related]
43. Leukotriene receptor antagonists for eczema.
Ferguson L; Futamura M; Vakirlis E; Kojima R; Sasaki H; Roberts A; Mori R
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD011224. PubMed ID: 30343498
[TBL] [Abstract][Full Text] [Related]
44. Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin.
Koenig MK; Hebert AA; Roberson J; Samuels J; Slopis J; Woerner A; Northrup H
Drugs R D; 2012 Sep; 12(3):121-6. PubMed ID: 22934754
[TBL] [Abstract][Full Text] [Related]
45. Drug interventions for the treatment of obesity in children and adolescents.
Mead E; Atkinson G; Richter B; Metzendorf MI; Baur L; Finer N; Corpeleijn E; O'Malley C; Ells LJ
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012436. PubMed ID: 27899001
[TBL] [Abstract][Full Text] [Related]
46. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
Curatolo P
Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis.
Li M; Zhou Y; Chen C; Yang T; Zhou S; Chen S; Wu Y; Cui Y
Orphanet J Rare Dis; 2019 Feb; 14(1):39. PubMed ID: 30760308
[TBL] [Abstract][Full Text] [Related]
48. Safety of Everolimus in Patients Younger than 3 Years of Age: Results from EXIST-1, a Randomized, Controlled Clinical Trial.
Jóźwiak S; Kotulska K; Berkowitz N; Brechenmacher T; Franz DN
J Pediatr; 2016 May; 172():151-155.e1. PubMed ID: 26858193
[TBL] [Abstract][Full Text] [Related]
49. Anti-TNF agents for paediatric psoriasis.
Sanclemente G; Murphy R; Contreras J; García H; Bonfill Cosp X
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD010017. PubMed ID: 26598969
[TBL] [Abstract][Full Text] [Related]
50. Response of subependymal giant cell astrocytoma with spinal cord metastasis to everolimus.
Aguilera D; Flamini R; Mazewski C; Schniederjan M; Hayes L; Boydston W; Castellino RC; MacDonald TJ
J Pediatr Hematol Oncol; 2014 Oct; 36(7):e448-51. PubMed ID: 24276039
[TBL] [Abstract][Full Text] [Related]
51. Interventions for chronic palmoplantar pustulosis.
Obeid G; Do G; Kirby L; Hughes C; Sbidian E; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011628. PubMed ID: 31958161
[TBL] [Abstract][Full Text] [Related]
52. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
Kotulska K; Chmielewski D; Borkowska J; Jurkiewicz E; Kuczyński D; Kmieć T; Łojszczyk B; Dunin-Wąsowicz D; Jóźwiak S
Eur J Paediatr Neurol; 2013 Sep; 17(5):479-85. PubMed ID: 23567018
[TBL] [Abstract][Full Text] [Related]
53. Clonazepam monotherapy for treating people with newly diagnosed epilepsy.
Brigo F; Igwe SC; Bragazzi NL; Lattanzi S
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD013028. PubMed ID: 35187637
[TBL] [Abstract][Full Text] [Related]
54. Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA).
Ebrahimi-Fakhari D; Franz DN
Expert Opin Pharmacother; 2020 Aug; 21(11):1329-1336. PubMed ID: 32338549
[TBL] [Abstract][Full Text] [Related]
55. Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial.
Curatolo P; Franz DN; Lawson JA; Yapici Z; Ikeda H; Polster T; Nabbout R; de Vries PJ; Dlugos DJ; Fan J; Ridolfi A; Pelov D; Voi M; French JA
Lancet Child Adolesc Health; 2018 Jul; 2(7):495-504. PubMed ID: 30169322
[TBL] [Abstract][Full Text] [Related]
56. Interventions for pityriasis rosea.
Contreras-Ruiz J; Peternel S; Jiménez Gutiérrez C; Culav-Koscak I; Reveiz L; Silbermann-Reynoso ML
Cochrane Database Syst Rev; 2019 Oct; 2019(10):. PubMed ID: 31684696
[TBL] [Abstract][Full Text] [Related]
57. Vitamin D supplementation for sickle cell disease.
Soe HH; Abas AB; Than NN; Ni H; Singh J; Said AR; Osunkwo I
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010858. PubMed ID: 28105733
[TBL] [Abstract][Full Text] [Related]
58. Presurgical Administration of mTOR Inhibitors in Patients with Large Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex.
Jiang T; Du J; Raynald ; Wang J; Li C
World Neurosurg; 2017 Nov; 107():1053.e1-1053.e6. PubMed ID: 28866062
[TBL] [Abstract][Full Text] [Related]
59. Clonazepam monotherapy for treating people with newly diagnosed epilepsy.
Brigo F; Igwe SC; Bragazzi NL; Lattanzi S
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31742671
[TBL] [Abstract][Full Text] [Related]
60. Treatments for seizures in catamenial (menstrual-related) epilepsy.
Maguire MJ; Nevitt SJ
Cochrane Database Syst Rev; 2019 Oct; 10(10):CD013225. PubMed ID: 31608992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
